BURLINGTON, Mass.–(BUSINESS WIRE)–PharmaEssentia Corporation (TPEx: 6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the appointment of Raymond Urbanski, M.D., Ph.D., as Head of Clinical Development and Medical Affairs for the U.S. subsidiary.
Dr. Urbanski brings distinctive expertise to PharmaEssentia as he takes on responsibility for the company’s U.S.-based medical strategy, including clinical development and expansion of the clinical and medical teams. An established clinical researcher, licensed clinician and pharmaceutical executive, Dr. Urbanski has more than 25 years of experience in research, clinical practice, and the pharmaceutical industry, and has developed and delivered new therapeutics across multiple therapeutic areas.
“After a range of experiences at both large and smaller companies, I am inspired by the opportunity at PharmaEssentia, which is so well matched to my passion to advance care in hematology/oncology,” said Dr. Urbanski. “I fully embrace the challenge ahead as we prepare for hopeful FDA approval of the first treatment for PV in the US, and I see a bright horizon to bring new, innovative thinking to the clinician dialogue in the MPN community.”
Prior to PharmaEssentia, Dr. Urbanski served as Chief Medical Officer (CMO) and President of GT Biopharma, Inc., a NK cell-based oncology start-up company. He was previously the CMO of MannKind Corporation, as well as at Mylan. Earlier, Dr. Urbanski spent almost a decade at Pfizer holding several positions, including CMO of the Established Products Business Unit and Senior Medical Director of the Oncology Clinical R&D group. Prior to industry, he spent three years in a private practice. Dr. Urbanski received his MD and PhD in Pharmacology from the New Jersey Medical School, and completed his Residency and Fellowship training at Thomas Jefferson University Hospital in Philadelphia where he conducted groundbreaking research on targeted chemotherapy.
“As we continue to build a strong team of experts to support our ambitions, we graciously welcome Dr. Urbanski to PharmaEssentia,” said Meredith Manning, General Manager of U.S. Operations. “His wealth of experience and renowned expertise will be a tremendous asset as we look to contribute in new ways to the MPN community.”
PharmaEssentia Corporation (TPEx: 6446) is a rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, the company aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one product already approved in Europe and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today the company is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung.